TABLE 1.
Demographic and baseline clinical characteristics.
| CAP (n = 25) | Itraconazole (n = 24) | p | |
|---|---|---|---|
| Age, years (median, IQR) | 28.0 (22.0, 34.5) | 24.5 (21.0, 32.8) | 0.548 |
| Female, n (%) | 10 (40.0) | 9 (37.5) | 0.858 |
| Fitzpatrick skin type, n (%) | 0.633 | ||
| II | 3 (12.0) | 2 (8.3) | |
| III | 13 (52.0) | 16 (66.7) | |
| IV | 9 (36.0) | 6 (25.0) | |
| Duration, days (median, IQR) | 17.0 (7.5, 36) | 15.5 (8.3, 27.8) | 0.528 |
| Distribution, n (%) | 0.907 | ||
| Face | 2 (8.0) | 1 (4.2) | |
| Neck | 3 (12.0) | 2 (8.3) | |
| Chest | 12 (48.0) | 14 (58.3) | |
| Abdomen | 0 (0.0) | 1 (4.2) | |
| Back | 7 (28.0) | 5 (20.8) | |
| Upper limbs | 1 (4.0) | 1 (4.2) | |
| Prior antifungal therapy, n (%) | 5 (20.0) | 3 (12.5) | 0.702 |
| Baseline DLQI (mean, SD) | 9.7 (5.5) | 8.9 (5.8) | 0.638 |
Abbreviations: CAP, cold atmospheric plasma; DLQI, Dermatology Life Quality Index.; IQR, interquartile range.